These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 22380577

  • 1. Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
    Lai PS, Chua SS, Chan SP.
    J Clin Pharm Ther; 2012 Oct; 37(5):536-43. PubMed ID: 22380577
    [Abstract] [Full Text] [Related]

  • 2. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS, Chua SS, Chew YY, Chan SP.
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [Abstract] [Full Text] [Related]

  • 3. Impact of pharmaceutical care on knowledge, quality of life and satisfaction of postmenopausal women with osteoporosis.
    Lai PS, Chua SS, Chan SP.
    Int J Clin Pharm; 2013 Aug; 35(4):629-37. PubMed ID: 23677816
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 5. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM.
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [Abstract] [Full Text] [Related]

  • 6. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [Abstract] [Full Text] [Related]

  • 7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.
    Int J Clin Pharmacol Res; 2004 Oct; 24(1):1-10. PubMed ID: 15575171
    [Abstract] [Full Text] [Related]

  • 8. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD, Möller G.
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [Abstract] [Full Text] [Related]

  • 9. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
    Cramer JA, Amonkar MM, Hebborn A, Altman R.
    Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
    [Abstract] [Full Text] [Related]

  • 10. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S, Agodoa I, Bonnick S, Van den Bergh JP, Ferreira I, Ho PR, Brown JP.
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [Abstract] [Full Text] [Related]

  • 11. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG, Brown JP, Beary JF, Matzkin E, Darbie LM, Burgio DE, Racewicz AJ.
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
    Josse R, Khan A, Ngui D, Shapiro M.
    Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
    [Abstract] [Full Text] [Related]

  • 16. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA.
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [Abstract] [Full Text] [Related]

  • 17. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W, Emkey R, Civitelli R.
    Drug Saf; 2007 May; 30(9):755-63. PubMed ID: 17722968
    [Abstract] [Full Text] [Related]

  • 18. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract] [Full Text] [Related]

  • 19. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE, Fosamax Actonel Comparison Trial Investigators.
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [Abstract] [Full Text] [Related]

  • 20. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
    Martens MG, Shaw H.
    South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.